About UsManagement Team
Board of Directors
Advisory Board

Board of Directors:
Steven Stice, PhD

Dr. Stice is a University of Georgia Research Alliance Eminent Scholar and the Director of the University of Georgia Regenerative Bioscience Center. He has an extensive background in animal health technology and stem cell applications along with an entrepreneurial record of successful companies generated from IP he developed. Dr. Stice was a co-founder and former Chief Scientific Officer at Advanced Cell Technology, Inc., a stem cell company with a market cap of $150 million. His current research activities are varied including working with the Bill and Melinda Gates Foundation to develop disease resistant livestock and developing stem cell therapies for Stroke and Parkinson’s. He has published and lectured internationally on stem cells throughout his career, with research findings highlighted in the NY Times, USA Today, Time Magazine, CNN, CBS, NBC and ABC News broadcasts.
  Joseph Patti, PhD

Joseph M. Patti, M.S.P.H., Ph.D. is currently the President and Chief Executive Office and Board Member of Biota Pharmaceuticals, Inc., a publicly traded biopharmaceutical company focused on the development of novel drugs to treat life-threatening viral respiratory infections. Previously, Dr. Patti was the Executive Vice-President, Corporate Development & Strategy at Biota. Prior to joining Biota, Dr. Patti was a co-founder of Inhibitex, Inc., a biopharmaceutical company developing novel therapeutics for a variety of bacterial and viral infections. Inhibitex was acquired by Bristol Myers Squibb in February 2012. Prior to the acquisition, Dr. Patti was Inhibitex’s Chief Scientific Officer as well as the Senior Vice President, Research & Development. Prior to founding Inhibitex, Dr. Patti was a Research Assistant Professor at Texas A&M’s Institute of Biosciences and Technology and was focused on the molecular aspects of bacterial - host interactions. From 1996 to 1998, he also served on the faculty at the University Of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, a M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham.
Linda Black, DVM, PhD
Chief Executive Officer

Dr. Black has 20 years of experience in human and animal healthcare, focusing on regenerative medicine and cellular therapy development since 2007. She led the clinical development strategy to add new indications for autologous adipose-derived stem cell therapy for dogs and horses with the first and largest veterinary regenerative medicine company. As VP of Product Development, Dr. Black led the development team for allogeneic FDA-regulated cell therapy products to treat osteoarthritis in dogs. She has consulted for numerous human and veterinary regenerative medicine and cell therapy companies. Dr. Black received a DVM from the University of Wisconsin-Madison and a PhD in Cell and Molecular Biology from the University of Pennsylvania , School of Medicine.